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FOREWORD 
Vision has a major influence on quality of life, and is perhaps even more important 
for the elderly, for whom mobility and the opportunity to adapt to new situations can 
be restricted. Age-related macular degeneration (AMD) is the most common cause of 
severe vision loss in the elderly population in the developed world. As the general 
Norwegian population is getting older, the prevalence of AMD will rise, resulting in 
an increased burden on patients and society. The anti-VEGF treatment with 
ranibizumab has shown considerable efficacy with respect to improvement of visual 
acuity among patients with neovascular AMD. However, there is also a cost side 
related to this treatment. Uncritical implementation of promising, but costly new 
treatments will have consequences in other parts of the health care system, which 
operates under scarce resources and seeks optimal allocation of its resources. 
Economic evaluation of health care programmes may be a useful tool for decision-
makers who strive for optimal resource allocation. Based on the issue of priority 
setting in the health care sector, the aim of this study was to explore whether the costs 
of replacing the conventional PDT treatment by treatment with ranibizumab on AMD 
patients can be justified by the improvement in efficacy.  
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ABBREVIATIONS AND ACRONYMS 
AMD Age-related macular degeneration 
CNV Choroidal neovascularization 
RPE Retinal pigment epithelium 
RAP Retinal angiomatic proliferation 
PDT Photodynamic therapy 
VEGF Vascular endothelial growth factor 
Fab Fragment, antigen binding 
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VA Visual Acuity 
EDTRS The early treatment of diabetic retinopathy study 
TAP Treatment of Age-related Macular Degeneration with Photodynamic Therapy 
ANCHO
R 
Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal 
Neovascularization in Age-related Macular Degeneration 
MARINA 
Minimally classic/occult Trial of the Anti-VEGF Antibody Ranibizumab in the 
treatment of Neovascular Age-related Macular Degeneration 
CUA Cost utility analysis 
ICER Incremental cost-effectiveness ratio 
QALY Quality adjusted life time 
HrQoL Health related quality of life 
CBA Cost benefit analysis 
CEA Cost effectiveness analysis 
TTO Time trade off 
SG Standard gamble 
NABP The Norwegian association of the blind and partially sighted 
NMA The Norwegian medicines agency 
NOK Norwegian kroner 
NPV Net present value 
RCT Randomized controlled trials 
PIER 
Phase IIIb, multicenter, randomized, double masked, sham injection-controlled 
study of the efficacy and safety of ranibizumab 
PRONTO 
prospective OCT imaging of patients with neovascular AMD treated with intra-
ocular lucentis 
FOCUS RhuFab v2 Ocular treatment combining the use of visudyne to evaluate safety 
(number) Reference 
wordª Footnote 
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ABSTRACT 
Background: Age-related macular degeneration (AMD) is the leading cause of severe vision 
loss in the developed world. Through clinical trials, treatment with ranibizumab has proved 
to be more effective than photodynamic therapy with verteporfin for AMD. The high price 
of ranibizumab, however, has raised questions about its cost-effectiveness. 
Methods: Three treatment options were considered in a cost-utility analysis adopting a 
health care perspective. A decision analytic model was developed to assign patients to four 
different health states over a 2-year time period. The model inputs were efficacy results of 
the treatment options in terms of probabilities, costs related to treatment options and vision 
loss. Costs were expressed in 2007 Norwegian Kroner (NOK), and the health outcome was 
measured in quality adjusted life years (QALYs). Quality of life weights were taken from a 
study associating time trade-off utility values with visual acuity levels, while the use of 
health care was based on expert judgment 
Results: When indirect costs were disregarded, the two-year costs of verteporfin, 0.3 mg and 
0.5 mg ranibizumab were NOK 198,500, NOK 314,500 and NOK 437,000, respectively with 
corresponding QALYs of 1.34, 1.50 and 1.51. The incremental costs of replacing verteporfin 
by 0.3 mg and 0.5 mg ranibizumab were NOK 116,000 and NOK 122,500 with incremental 
QALYs of 0.16 and 0.015. The incremental cost-effectiveness ratios were NOK 739,500 and 
NOK 7,976,000, respectively. 
Interpretation/conclusion: The results of this study indicate that neither treatment with 0.3 
mg ranibizumab nor treatment with 0.5 mg ranibizumab is cost-effective as replacement of 
the conventional PDT treatment when NOK 425,000 is defined as the threshold for 
incremental costs per QALY. This conclusion may change if it were documented that two 
year treatment with ranibizumab has benefits beyond the treatment period. The treatment 
option with 0.3 mg ranibizumab would be cost-effective if the drug costs per dose of 
ranibizumab were reduced from NOK 9,190 to NOK 6,900 (excl. VAT).  
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1. INTRODUCTION 
Age-Related macular degeneration is a disease associated with aging that gradually 
destroys the macula, which is responsible for the sharp, central vision. It is the 
leading cause of severe vision loss amongst the elderly population in the developed 
world. In epidemiological studies, an age of 50 years old is arbitrarily chosen as the 
minimum age for the diagnosis of AMD (1). The exact cause of the disease is 
unknown. However, the prevalence increases with higher age, and there are also 
identified certain risk factors including female sex, Caucasian origin and cigarette 
smoking (2). Additionally, it is suggested that the immune system has an important 
role in AMD (3). 
1.1 Antibodies 
The immune system is supposed to play an essential part in both the development of 
AMD, but also in the anti-VEGF treatment of AMD with ranibizumab. Because of 
this, it is necessary to describe some basic principles of immunology, especially 
related to the function of the antibodies. The function of the immune system is to 
defend the body against pathogens. Pathogens are biological agents that can cause 
illness or diseases to the body. The pathogens contain antigens1, which stimulate the 
body to initiate an immune response. A normal immune response consists of 
recognizing a foreign antigen, mobilize forces to defend against it, and then attacking 
it (4). The immune system contains many different parts with highly specific 
functions, which in combination form an effective defence mechanism that protects 
the body. However, in relation to AMD and the treatment with ranibizumab, it is the 
antibodies that are of most importance. Hence, I will put emphasis on the function of 
the antibodies in this part of the paper. 
                                              
1 Any substance that can stimulate an immune response is called an antigen. 
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The antibodies, also called immunoglobulins, are large Y-shaped proteins that are 
used by the immune system to identify and neutralize pathogens (Fig. 1). 
Figure 1: Basic structure of an antibody 
 
 
 
The antibodies consist of two fragments; the Fragment crystallisable (Fc) region and 
the Fragment antigen binding (Fab) region. The Fc region2 is a constant part derived 
from the stem of the Y, and consists of two heavy chains of amino acids. This part 
determines the class of the antibody (IgG, IgM, IgD, IgE or IgA) and binds to 
receptors, such that an immune response is initiated. The Fab region3 is a variable 
part that binds to specific antigens. This part varies among the antibodies depending 
on which antigen it is targeting (4). 
 
                                              
2 Illustrated as the constant part in figure 1. 
3 Illustrated as the variable part in figure 1. 
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The identification process is done by the antibody recognizing certain targets, the 
antigens, and then binding to that specific antigen. After binding to the antigen, the 
antibodies bind to specific cellular receptors, so that other parts of the immune system 
can activate an appropriate immune response, and destroy that given antigen. The 
binding of antibodies to antigens can also neutralize the antigens directly, as it 
prevents the antigens to bind to the receptors they need to promote their type of 
illness. 
1.2 Anatomy and Physiology of the Eye 
AMD is a retinal disorder which affects the macula. The retina is a multi-layered 
sensory tissue on the inner surface of the back of the eye. It contains millions of 
photoreceptors that capture light rays and convert them into electrical impulses that 
are carried to the brain by the optic nerve. In the brain these electrical impulses are 
again turned into images. There are two types of photoreceptors in the retina: rods 
and cones. The cones are responsible for high-resolution and color vision (1). The 
cones are contained in an area of the retina called macula lutea, and function best in 
bright light. In the centre of the macula lies a pit called fovea centralis, which 
contains the highest density of cones. The preponderance of cones over rods in this 
area, make the fovea responsible for our sharp central vision. Hence, when we focus 
on a detail, the muscles in the eye focus the image of the detail to the fovea centralis 
(5). The rods are spread throughout the retina, and are responsible for the peripheral 
vision and the night vision. Because AMD is a disorder that affects the macula, 
patients will lose their sharp central vision, while their peripheral vision is 
maintained. However, in severe cases of central visual loss, the condition can be 
compared to being blind, as the patients are incapable of reading, recognizing people, 
movement on their own, etc. AMD is classified as a retinal disorder (4), and it is 
therefore necessary to describe some details of the structure of the retina and its 
function.  
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The retina consists of several distinct layers, which form the back of the eye. The 
inner retina is adjacent to the vitreous and the outer retina is adjacent to the choroid 
(Fig. 2). 
Figure 2: Anatomy of the eye 
 
 
 
Age-related changes that predispose a person to AMD, occur in the outer retina. The 
outer retina includes the outer segments of the photoreceptors, the retinal pigment 
epithelium (RPE) and Bruch’s membrane (Fig. 3). The adjacent choriocapillaris, the 
capillary layer of the choroid, is the vascular system that feeds the outer retina. These 
structures, collectively called Ruysch’s complex, provide an optimal environment for 
retinal function, that provides vision of high resolution, color vision, peripheral vision 
and vision at dusk (1).   
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Figure 3: Normal fundus – interior surface of the eye 
 
Figure 3: The outer 
circle shows macula 
lutea, while the inner 
circle represents fovea 
centralis. The inset shows 
the outer layers of the 
retina. The graph 
visualizes a coherence of 
the distance of a scar 
from the fovea, caused by 
AMD, and the drop in 
visual acuity (1).  
The photoreceptors are specialized types of neurons that convert light into nerve 
signals, as electrical impulses. This is done by a change in the cells membrane 
potential when they absorb light (photons). These signals are sent to other neurons, 
ultimately sent to the brain by the optic nerve, and produce images.  
 
The RPE is a pigmented4 cell-layer, which has a central element in the pathogenesis 
of AMD. The RPE cells derive their name from the numerous melanosomes5 within 
their cytoplasm. The most important functions of the RPE are to regenerate bleached 
                                              
4 A pigment is a material that changes the color of light it reflects as the result of selective color absorption. 
5 A melanosome is an organelle containing melanin, the most common light-absorbing pigment in the body. 
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visual pigments; formation and maintenance of the extracellular matrix6 in Bruch’s 
membrane, and transportation of fluids and ions between photoreceptors and the 
choriocapillaries (1). The RPE is also phagocytic7 system that is essential to the 
renewal of photoreceptors. However, residues from this process are also a burden on 
the RPE cells as the metabolic waste is accumulated over a lifetime resulting in 
conditions that can promote the development of AMD (1).  
 
Bruch’s membrane consists of three layers, and lies between the RPE and the 
choriocappilaries. Its function is to transport substances between the RPE and the 
choriocappilaries, to maintain the survival of the RPE-cells. As a person is getting 
older this membrane calcifies and becomes thicker. As a result of this, the 
permeability of the membrane decreases, and basal laminar deposits and membranous 
debris is kept within the membrane. This leads to the formation of drusen, a common 
sign of early AMD. The decreased function of Bruch’s membrane also results in 
diminished cell adhesion and anoikis. Anoikis is a form of apoptosis8 resulting from 
incorrect cell adhesion. This results in extracellular deposits around Bruch’s 
membrane, which may lead to local inflammation. This inflammation, again 
promotes the development of AMD (1). 
 
Ruysch’s complex receives its blood supply from the choriocappilaries, which has 
extensive fenestration to Bruch’s membrane. Ruych’s complex demands high levels 
of oxygen compared to the inner retina due to the photoreceptors that consume more 
than 90% of this oxygen. With increasing age, the lumina of the choriocappilaries and 
the choroidal thickness are reduced. This, together with a thinning or destruction of 
                                              
6 Extracellular matrix is any material of a tissue that is not a part of any cell. 
7 Phagocytosis is an immune response to control inflammation. 
8 Apoptosis is a type of deliberate programmed cell death in multicellular organisms.  
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the RPE, can result in a hypoxic environment9 in Ruych’s complex. The hypoxia 
increases the secretion of growth factors such as vascular endothelial growth factor 
(VEGF)-A within Ruych’s complex. The VEGF-A causes the development of 
choroidal neovascular membranes, which result in the formation of new abnormal 
blood vessels. Leakage from these vessels are the main pathogenesis of neovascular 
AMD (1).    
1.3 Forms and Stages of AMD 
AMD can be divided into various forms and stages. The two clinical stages of AMD 
are categorized as early, in which visual symptoms are inconspicuous, and late, in 
which severe vision loss is usual. The early stage of AMD is always the atrophic form 
of the disease, while the late stage can be either categorized as atrophic or 
neovascular (1). This paper concerns treatment on neovascular AMD, and it will be 
emphasized on this condition. Another important feature of AMD is that the disease 
does not necessary appear in both eyes, but can appear in one eye independently of 
the other. The different forms of the disease, atrophic and neovascular, can vary 
between the eyes, but also within each eye (1). 
1.3.1 Atrophic AMD 
The atrophic, or dry form, of AMD is the most common, and constitutes about 90% 
of all cases of AMD (6). This is a condition characterized by a slowly progressive 
decline in central vision, which can develop over decades.  Dry AMD is characterized 
by the appearance of drusen that build up in Bruch’s membrane or by 
hyperpigmentation or hypopigmentations of the RPE (1). These phenomena can 
result in an atrophy10 of the RPE that causes a loss of central vision. Drusen are tiny 
                                              
9 Hypoxia means shortage of oxygene. 
10 Pathologic athrophy is a decrease in the size of a body organ or tissue, caused by a disease, injury, or lack of use. 
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yellow or white accumulations of extracellular material, which can vary in numbers 
and size. The size of the area on the RPE affected by hyper- or hypopigmentation 
does also vary to a large extent. The development of drusen, hyper- or 
hypopigmentation is a normal part of the aging process. However, increased size and 
numbers of drusen, and/or area of pigmentation on the RPE, implicate an increased 
risk of the condition developing into the late stage, or to the much more serious 
neovascular form (1). Currently, there are documented no effective treatments for dry 
AMD, but it is important to follow up these patients to see how the disease develops. 
A patient will have benefits of early treatment, if the condition develops from 
atrophic to neovascular AMD.  
1.3.2 Neovascular AMD 
The neovascular, or wet, form of AMD is a much more aggressive form of the 
disease. Even though it affects only approximately 10% of the patients with AMD, it 
is responsible for about 90% of the cases leading to severe vision loss (6). Without 
any treatment of this condition, patients will experience a severe and rapid decline in 
central vision, during a period of time between 3-24 months (6). The wet form of 
AMD is characterized by the growth of new, abnormal blood vessels within or under 
the macula. Leakage from these vessels, termed neovascularization, results in scar 
formation in the macula and/or RPE detachment from Bruch’s membrane, which 
again is responsible for the vision loss. If the new blood vessels originates, and 
penetrate the RPE from the choroid under the macula causing neovascularization, it is 
termed choroidal neovascularisation (CNV) (7). Neovascularization, originated in the 
retina, that extends to subretinal space is called retinal angiomatous proliferation 
(RAP) (8). CNV and RAP are also classified by fluorescein angiograpgy11 into 
angiopraphic patterns termed “classic” and “occult”, which are associated with 
different degrees of aggressiveness related to vision loss and response to treatment 
                                              
11 Angiography, or arteriography, is a medical imaging technique in which an X-ray picture is taken to visualize the inner 
opening of blood filled structures. 
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options (7). Often, the lesions are a mix of these two patterns, classified as 
predominantly classic and minimally classic. Predominantly classic means that the 
classic part of the entire lesion is more than 50%, while minimally classic means that 
the classic part of the lesion is below 50% of the lesion (9). When related to possible 
treatments options, it is also of importance where the lesions are located in the 
macula. Subfoveal CNV is located beneath the fovea, while extrafoveal CNV is 
located beside the fovea.  
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2. EPIDEMIOLOGY 
AMD is the leading cause of severe vision loss in the developed world among people 
50 years of age and older. This vision loss is mainly due to the neovascular form of 
the disease, which accounts for about 90% of these cases. Few epidemiological 
studies of AMD are done in Norway, but there is no reason to believe that the 
incidence and prevalence rates in Norway differ greatly from other similar 
populations. The reason for this is that the main risk factor of getting AMD is 
increasing age, as both the incidence and prevalence rates increase with higher age. 
The Oslo Macular Study (10) have also concluded that the prevalence of neovascular 
AMD in the Oslo area is similar to results achieved in epidemiological studies on 
other populations. Hence, I have extrapolated data from epidemiological studies done 
in the US to describe the incidence- and prevalence rates of AMD in Norway. A 
meta-analysis of population-based data performed by the Eye Disease Prevalence 
Research Group (11) estimated the prevalence of neovascular AMD on white 
participants aged over 40 years old, with age-specific prevalence rates12. Compared 
to numbers from the US Census 2000 Population13, this resulted in a prevalence of 
neovascular AMD to be 1.19% among the white population aged 40 years and older 
in the US. Based on data from Statistics Norway14, this indicated a prevalence of 
neovascular AMD in Norway to be about 26,130 persons in 2006. 
 
The yearly incidence of neovascular AMD in Norway was also extrapolated from 
data from the US. An article by Brown et al. (12) used the Beaver Dam Eye Study 
(13) and the Eye Disease Prevalence Research Group (11) to estimate the yearly 
                                              
12 See appendix 1 
13 http://www.nei.nih.gov/eyedata/tables.asp 
14 See appendix 2 
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incidence of neovascular AMD in Canada to be 5.26 per 10,000 inhabitants. 
Extrapolated to the Norwegian population this means about 2,440 new cases of wet 
AMD in Norway per year15. 
 
A population prediction 20 years from now, predicted by Statistics Norway, indicated 
a prevalence of AMD to be about 31,920, which means an increase of approximately 
22% in the prevalence of today. This indicates a yearly incidence of AMD to be 
about 2,775 persons in 2027. 
                                              
15 Based on a Norwegian population of 4,640,219 per 1st of January 2007 (Statistics Norway) 
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3. TREATMENT OPTIONS 
There are currently no effective treatments of dry AMD. However, a clinical trial 
called The Age-Related Eye Disease Study, AREDS (14), sponsored by the US 
National Eye Institute, suggests that the use of antioxidant vitamins and Zinc could 
slow down the progression of dry AMD to more advanced states. For wet AMD, 
there are several types of treatments, whose effectiveness are dependent on how the 
condition is classified. This analysis focused and compared two of these treatments, 
namely the photodynamic therapy with verteporfin16, and the anti-VEGF therapy 
with ranibizumab17. The experiences with treatments of wet AMD until the 
introduction of ranibizumab, were that the prior treatments only tended to slow down 
the processes of the vision loss, while ranibizumab also has shown improvement in 
the vision of the patients treated. In this paper I have used the visual acuity scale as 
the measurement of sharp, central vision, as this is a common clinical measurement of 
visual function.  
3.1 Visual Acuity Scale 
Measurement of the visual acuity has often been performed by using the Snellen chart 
(Fig.4). The patient covers one eye, and starts reading form the top. The smallest line 
the patient is able to read represents the visual acuity of that eye. Both eyes are tested, 
and the visual acuity is defined by the best functioning eye 
                                              
16 Visudyne® is the commercial name for verteporfin. 
17 Lucentis® is the commercial name for ranibizumab. 
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Figure 4: The Snellen chart 
 
 
 
Normal sight has the value of 20/20 on the visual acuity scale, which means being 
able to read line 8 in the figure, at the distance of 20 feet. A value of 20/40 indicates 
that the person is only capable of reading a line at 20 feet, which a person with 
normal sight is able to read at 40 feet. A person is considered legally blind if the best 
corrected visual acuity is defined as 20/200 or less (4). Today, EDTRS charts are 
widely used for measuring visual acuity (Fig. 5).  
Figure 5: The EDTRS chart 
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The principles are the same as the Snellen chart, but there are made adjustments in 
the design of the chart to correct for some methodological deficiencies that the 
Snellen chart has been critized for. Hence, the EDTRS chart is claimed to give a more 
accurate measurement of visual acuity than the Snellen chart (15). Based on these 
charts, visual acuity can be measured according to the number of letters or lines 
gained/lost by the patient.  
3.2 Photodynamic Therapy with Verteporfin 
Until the introduction of anti-VEGF therapy, photodynamic therapy (PDT) with 
verteporfin was the treatment option that provided the best clinical results on AMD 
patients with subfoveal neovascularisation. The limitation of this treatment is claimed 
to be that it only slows down the progression of the disease, with no improvement of 
the sight of the patients. Another limitation is related to the fact that PDT treatment 
has only been proved effective on predominantly classic CNV (16). The Sintef 
Report 3/2000 (6), estimated that about 40% of the patients with wet AMD is 
receptive to PDT treatment. 
 
PDT treatment was introduced during the 1980’s for treatment of cancer. It uses 
different kinds of light-activated drugs to treat a wide range of medical conditions. 
Any disease in which there is fast-growing tissue, abnormal blood vessels included, 
can potentially be treated with this technology. PDT with verteporfin was the first 
pharmacological treatment approved for subfoveal CNV as a result of AMD (17). 
 
PDT treatment with verteporfin is a two-step process involving an intravenous 
injection of verteporfin, usually through a vein in the arm of the patients, with a 
subsequent activation of the drug by light at wavelength 689 nm, delivered by a non-
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thermal laser. The injection lasts for about 10 minutes, the patient then waits for 
about 15 minutes while the drug is absorbed in the endothelial cells of the abnormal 
blood vessels causing AMD. The photoactivation lasts for exactly 83 seconds18, and 
generates short-lived reactive oxygen species that cause localised damage to the CNV 
endothelial cells. This leads to the destruction of the abnormal blood vessels, with 
minimal damage to the overlying retina (17). 
 
PDT with verteporfin is typically given about every 3 months and as many times as 
needed to prevent regrowth of the abnormal vessels. For most people, this involves 6 
to 7 treatments over 2 to 3 years. The treatments are normally performed in a doctor's 
office on an outpatient basis. In average, treatment is required 3.4 times the first year 
and 2.1 times the second year (18). 
3.3 Anti-VEGF Therapy with Ranibizumab 
Angiogenesis19 is a key aspect in neovascular AMD, and substantial evidence has 
indicated that VEGF-A is a major mediator of angiogenesis and vascular leakage in 
wet AMD (19). VEGF-A is the prototype member of a gene family that also includes 
a sub-family of other growth factors such as VEGF-B, VEGF-C, VEGF-D and the 
placenta growth factor. These are signalling proteins, whose activities mainly are 
restricted to the cells of the vascular endothelium20. VEGF-A exists in several 
isoforms generated by alternative mRNA splicing. All these isoforms, which are 
separated by the number of amino acids they contain, may enhance the pathological 
angiogenesis of neovascular AMD by binding to receptors on the endothelial cells 
and stimulating cellular responses that cause the formation of new blood vessels. 
                                              
18 http://www.visudyne.com/info/treating/photodynamic-therapy.jsp 
19 Angiogenesis is the physiological process involving the growth of new blood vessels from pre-existing vessels. 
20 The endothelium is the layer of cells lining the interior surface of blood vessels.. 
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Ranibizumab, the antibody fragment in Lucentis®, is a high affinity21 Fab that binds 
to all isoforms of VEGF-A. This results in a neutralization of VEGF-A because it 
blocks VEGF-A from binding to its receptors (19). Ranibizumab is produced in 
Echerichia coli cells deriving from a mouse anti-VEGF monoclonal antibody, and are 
genetically engineered through a process of selective mutation to increase its affinity 
for binding and inhibiting the growth factor (20) (Fig. 6).  
Figure 6: Production process of ranibizumab 
 
 
 
Treatment with ranibizumab was approved for use on AMD patients in June 2006 by 
the FDA in the USA, while the treatment in Norway was approved in March 2007. 
Some clinics, however, have got exemption for performing this treatment before the 
Norwegian approval, e.g Retinaklinikken in Oslo, which started this treatment as 
early as October 2006.  
                                              
21 Affinity is the binding strength of a single antibody (www.wikipedia.org). 
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The treatment consists of an intravitreal injection of ranibizumab (Fig. 7). Prior to the 
injection the patient should self-administer anti-microbial drops 4 times daily for 3 
days before and following each injection. The injection procedure should be carried 
out under sterile conditions, and an adequate anaesthesia and a broad-spectrum 
topical microbicide22 should also be administered prior to the injection. The injection 
needle is inserted in the vitreous cavity, and the site of the injection should be rotated 
for subsequent injections. Lucentis® are delivered in vials containing 3.0 mg of 
ranibizumab in a 0,3 ml solution, and are recommended for use at a monthly basis23.  
Figure 7: Intravitreal injection of ranibizumab 
 
 
                                              
22 A microbicide is any compound or substance whose purpose is to reduce the infectivity of microbes  
23 Based on the Official EU Prescribing Information of Lucentis® 
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3.4 Other treatments 
Another treatment that has been widely used on AMD patients, is the conventional 
laser treatment aiming to destroy the abnormal blood vessels. However, this treatment 
can only be used on extrafoveal CNV as the laser also destroys the macula. In 
addition to being restricted to few patients (about 15% of the cases) it has been 
documented that successful laser treatment often followed by a subsequent subfoveal 
CNV (21).  
 
There are also several treatments that are under consideration, and which effects are 
being under study. Some of them are: surgical movement of the macula; radiation 
therapy on the macula; thermo therapy of the macula; and transplantation of retinal 
cells.  
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4. ECONOMIC EVALUATION 
A full economic evaluation can be defined as the comparative analysis of alternative 
courses of action in terms of both their costs and consequences (22). Economic 
evaluations are useful tools to make “right” decisions in situations where resources 
are scarce, and can be applied in a lot of different settings. Hence, it is important to 
describe what perspective the analysis is based on. The basic tasks of any economic 
evaluation is to identify, measure, value and compare costs and consequences of the 
alternatives being considered in an incremental analysis, which means that the 
difference in costs is compared with the difference in consequences (22). Full 
economic evaluations are often classified into three different approaches: Cost-
Benefit Analysis (CBA), Cost-Effectiveness Analysis (CEA) and Cost-Utility 
Analysis (CUA). In short, these methods are primary distinguished according to how 
the consequences are being measured. Because, this paper is a CUA, I will describe 
the basic concepts of this method. 
4.1 Cost-Utility Analysis 
In CUA, the incremental cost of a programme from a particular viewpoint is 
compared to the incremental health improvement attributable to the programme, 
where the health improvement is measured in quality-adjusted-life-years (QALYs) 
gained. The results are expressed as a cost per QALY gained (22). 
CUA has its background in utility theories describing rational behaviour under 
uncertainty, which means maximising individual utilities. Because of this, a central 
topic of this kind of economic evaluation is that it highlights the role of consumer 
preferences (utilities) in valuing the outcome. Another important aspect of CUA is 
that the outcomes are measured on an interval scale and made generic (22). This 
makes it possible to compare the benefits of different programmes within the health 
care sector across diagnosis, patient groups etc. The CUA are, however, dependent on 
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being compared to an external standard to assess whether a specific programme is 
worthwhile or not. These external standards are often budget constraints or threshold 
cost-effectiveness ratios, used by the decision makers to maximize the benefits with a 
given budget. (22). The most comprehensive use of cost-effectiveness ratio is to 
analyse the incremental cost-effectiveness ration (ICER), which is the ratio between 
the difference in cost and the difference in benefits of two interventions. This is 
illustrated by equation 1, where c=costs and E=health benefits. 
Equation 1: 
12
12
EE
CCICER −
−=  
The cost analysis in a CUA is dependent on which perspective is chosen for the 
analysis. It is often preferred that the analysis is performed from a societal 
perspective, which means that all costs and health consequences shall be captured 
irrespectively of who pays or who benefits (23). The costs to be included in such a 
perspective are all relevant resources consumed by implementing the relevant health 
care programme24, and can be divided into the following cost items: health sector 
costs; costs on other (public) sectors; patient/family (time) costs and productivity 
losses. After identifying the relevant costs, the cost analysis consists of measuring the 
quantities of resources used and valuing them by assigning unit costs or prices (22). 
The final cost of the health care programme is then measured in monetary units. 
 
The most commonly used measurement of health outcomes in CUA are the QALY. 
The advantage of the QALY as a measure of health outcome is that it can 
simultaneously capture gains from reduced morbidity (quality gains) and reduced 
mortality (quantity gains), and combine these into a single measure (22). It combines 
                                              
24 Opportunity costs 
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health related quality of life (HRQoL) with a time perspective, and can be expressed 
with the following equation, where H = HRQoL and T = expected lifetime with H.  
Equation 2: 
THQALY ×=  
To be able to operationalize this equation, the difficult part is related to how the 
HRQoL is weighted. There are various methods for measuring the quality of life 
aspect, which means measuring individual preferences for different health states. Two 
of the most commonly used techniques for this purpose are the time trade-off method 
(TTO) and the standard gamble method (SG). In addition there are developed various 
generic descriptive systems for health, that assign preference scores to different 
health states according to how well the individual functions in different dimensions 
like, e.g mobility, self-care, pain, vision etc. Examples of such generic descriptive 
systems are EQ-5D, SF-6D and Health Utilities Index (HUI-II and HUI-III). To 
satisfy the QALY concept, the quality weights must meet the following three 
requirements: (22) 
1) be based on preferences 
2) be anchored on perfect health (H=1) and death (H=0) 
3) be measured on an interval scale 
Following from this, the QALY concept is a measure of health gains that can be 
compared across diagnosis. It also considers the duration of time that individuals 
spend in the different health states. 
5. RESEARCH QUESTION 
What is the incremental cost and health benefit of replacing PDT with verteporfin by 
anti-VEGF treatment with ranibizumab for patients with predominantly classic 
neovascular AMD in Norway from a health care perspective over a time period of 2 
years?  
The core issues of the economic evaluation are listed in the table below. 
Table 1: Core issues in the economic evaluation 
Issues   
Comparators PDT with verteporfin, anti-VEGF treatment with ranibizumab  
Perspective Health care 
Patient group A Norwegian population in the age group 70-80 years old 
Evidence of 
effectiveness 2 different phase III clinical trials; ANCHOR and TAP  
Duration of treatment 2 years 
Type of economic 
analysis CUA performed within a decision tree modell  
Utilisation of health 
states Based on published article Brown et al 2005  
Unit costs Market prices, fee schedules, wage rates in the public sector  
Quality of life measure QALYs  
Time horizon 2 years  
Discount rate 4%  
Sensitivity analysis One-way 
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6. METHODS  
To get an answer to my research question I developed a decision analytic model and 
performed a CUA. The model was designed and conducted in the software 
programme TreeAge. The inputs of the model, that is data regarding costs, 
effectiveness and utilities are derived from published articles, expert opinions and 
own estimates. 
6.1 Despription of the Decision Analytic Model 
The decision analytic model was performed as a decision tree. The model simulates 
three strategies: treatment with 0,5mg ranibizumab; treatment with 0,3mg 
ranibizumab and photodynamic therapy with verteporfin over a 2-year time period. 
The model starts with patients with an average of 75 years old, suffering from 
predominantly classic AMD with a visual acuity (VA) of 20/80. The age of 75 years 
old was chosen based on the baseline characteristics of the study population of the 
TAP-study (74.9 years) (16) and the ANCHOR study (76.0 years) (24). It was 
assumed that the patients were in perfect health apart from the AMD diagnosis, so 
that all changes in HRQoL were due to changes in visual acuity caused by AMD. 
From the initial state, I have assigned the patients to end up in 4 different health states 
according to VA. These health states were defined to be: 
(1) VA ≥ 20/40    
(2) 20/40 > VA ≥ 20/80 
(3) 20/80 > VA ≥ 20/160  
(4) VA < 20/160 
I have estimated probabilities of ending up in each state over the time interval, and 
each state has also been assigned specific costs and quality of life values. The model 
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follows the patients for two years, and it is assumed that potential improvement of 
sight is obtained during the first year. This means that the patients only will maintain 
or lose vision during year 2. The structure of each main branch of the decision tree, 
representing the different treatment options, is identical. A simplified version of the 
decision tree is shown in Figure 8. 
Figure 8: The decision analytic model 
 
 
6.2 Literature Search 
The first process of conducting the study was to perform a literature search to get an 
overview of relevant aspects for my study. I have prioritized my literature search on 
published articles in the PubMed database containing at least one of the following 
keywords: age-related macular degeneration; AMD; VEGF; Ranibizumab; Lucentis; 
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Photodynamic therapy; PDT; Verteporfin; Visudyne; epidemiology; prevalence; 
incidence; costs; cost effectiveness; cost-utility analysis; CUA.  
 
One major inclusion criterion for choosing which articles to focus on was how the 
efficacy results in the articles were proved. Related to efficacy, only articles based on 
randomized controlled trials (RCT) were considered. For articles describing the 
effectiveness of ranibizumab, I have emphasized articles presenting the clinical 
results of the ANCHOR-(24) and the MARINA studies (25), both phase III clinical 
trials. The ANCHOR study is a comparison of the effectiveness of ranibizumab 
versus verteporfin in treatment of predominantly classic neovascular AMD, while the 
MARINA study is describing the effectiveness of ranibizumab on either minimally 
classic or occult CNV compared to sham injection. These two articles were published 
in a series of articles describing AMD in The New England Journal of Medicine. On 
the more general description of AMD, and the mechanism of disease I emphasized 
another article in this series, by deJong, P.T.V.M. (1).  
 
When it comes to articles related to the effectiveness of PDT with verteporfin, I have 
chosen to include different reports from the TAP study group (16;18;26). This study 
group has published several reports regarding effectiveness of PDT on different 
subgroups of AMD, and also long-term effects of PDT treatment based on RCTs. For 
the best comparison to the ANCHOR study, I emphasized the TAP Report No. 8 
(26), which described the efficacy of PDT on predominantly classic CNV over a 5-
years time horizon.  
 
In the data regarding the epidemiology of AMD, I have used articles based on the 
Beaver Dam Eye Study (13) as reference case because there are few studies related to 
the epidemiology of AMD in Norway. The extrapolation of data from the US was 
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supported by The Oslo Macular Study (10) and the SINTEF Report nr. 3/2000 (6), 
which conclude that the prevalence and incidence of AMD in Norway have 
similarities to those of similar populations. Because populations of Caucasian origin 
seems to have increased risk of developing AMD (11), I have only considered the 
prevalence- and incidence rates of the white population in the US when extrapolating 
to Norwegian conditions.  
 
Utility values for the different levels of visual acuity were derived from a study by 
Brown et al.(27). This study is referred to by many other articles describing quality of 
life aspects regarding AMD, and has measured utility values associated with visual 
acuity levels based on a TTO method. 
 
6.3 Probabilities 
As mentioned in the context of the literature search, the efficacy of treatment with 
verteporfin and ranibizumab was based on respectively the TAP Reports and the 
ANCHOR trials25. The efficacy results from these clinical trials are reported in either 
lines gained/lost at a Snellen chart, or letters gained/lost on an EDTRS chart, where 5 
letters on the EDTRS chart equals 1 Snellen line. Related to VA, losing15 letters or 3 
lines represent a doubling of the visual angle (28), e.g going from a VA of 20/40 to 
20/80. The primary outcomes in TAP and ANCHOR were proportion of patients 
losing fewer than 3 lines / 15letters. With these requirements, I have translated the 
results from the TAP reports and the ANCHOR study26 , to probabilities of being in 
one of the four states after one year of treatment, with an initial VA of 20/80. This 
                                              
25 See appendix 3 
26 See appendix 4 
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translation was made by dividing the proportion of patients into groups of change in 
VA. These groups were: 
1. VA gain ≥ 3-lines /15 letters 
2. 0 ≤ VA gain < 3-lines /15 letters 
3. 0 < VA loss ≤ 3-lines / 15 letters 
4. VA loss < 3-lines / 15 letters 
The proportions of these groups were then used to estimate the probabilities of being 
in one of the defined health states after one year of treatment when the initial VA was 
set to be 20/80. The proportion of patients in group 1 was equal to the probability of 
ending up in health state 1, the probability of being in health state was equal to the 
proportion of patients in group 2 etc. 
 
The transition probabilities with treatment of 0.5 mg ranibizumab were estimated 
from the ANCHOR study, supplied with the subgroup analysis.  Because the 
subgroup analysis did not include treatment with 0.3 mg ranibizumab, I estimated 
these probabilities on the assumption that treatment with 0.3 mg of ranibizumab 
followed the same distribution as treatment with 0.5 mg of ranibizumab.  Because the 
published data of treatment with ranibizumab is restricted to the 1-year results, I also 
had to estimate how these data would be after 2 years. After a consultation with 
David M. Brown, MD, the main author of the article describing the results of the 
ANCHOR trials in The New England Journal of Medicine (24), I estimated the 2-
year results based on his expert opinion. He reported that the 3-line gainers were 
quite constant at 24 months, and a decline in patients losing fewer than 3 lines of 4-5 
% for all treatment options. From this information I estimated the 2-year efficacy 
results of treatment with ranibizumab. When it comes to the clinical results of PDT 
treatment, I found that these results differed substantially between the TAP reports 
and the ANCHOR trial even when the results derived from patients with 
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predominantly classic CNV. Because of this, I used the mean of the results from these 
trials. However, I used the same assumptions regarding the coherence between the 1-
year and 2-year results as I did with ranibizumab. The probabilities used in the model 
are listed in appendix 4.The upper and lower bounds are determined by a 95 % 
confidence interval as reported in TAP (16) and ANCHOR (24), and calculated in 
Microsoft Excel. The max limit of the upper and lower bound was set to 0 and 1, 
because the values are probabilities. 
6.4 Costs 
In a societal perspective, all costs are included in the economic evaluation. I have 
excluded all indirect costs related to productivity losses and time consumption by e.g. 
family members and volunteers. Hence, the perspective of the CUA was narrowed to 
a health care perspective. From a health care perspective, costs related to adverse 
effects and injuries caused by impaired vision were excluded. All the excluded costs 
were due to limitations of available data.  
 
The costs that were identified, measured and valued in my model was drug costs of 
ranibizumab and verteporfin, other costs related to giving the treatments, costs of 
physician visits, costs of vision aids related to levels of visual acuity, costs of nursing 
care (homecare) and costs related to rehabilitation. In general, the limitation of 
available data was substantial in the cost analysis. As a result of this, the costs were 
estimated to a greater extent on assumptions. All costs were measured in Norwegian 
Kroner (NOK), and presented in Table 2 (p. 40). The ranges of the upper and lower 
bounds were determined by the base case value +/- 20 %. 
6.4.1 Drug Costs   
The unit cost of verteporfin was defined as the price of one single dose of verteporfin 
(15 mg), with the assumption of one dose used per treatment. This cost was derived 
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from the Norwegian Medicines Agency (NMA)27, where maximum pharmacy sales 
price28 was subtracted 25% VAT, resulting in a unit cost of NOK 9,790. The 
frequency of treatment with verteporfin was 3.4 treatments the first year, and 2.1 
treatments the second year (18). The upper and lower of the frequency in the first 
year were set to 5 and 2.5, while these bounds were set to be 3.5 and 1 in the second 
year. 
Because treatment with ranibizumab can be given in doses of 0.3 mg and 0.5 mg, the 
unit cost of ranibizumab was defined to be the price of 0.1 mg ranibizumab. One 
single dose of Lucentis®, sold by pharmaceuticals, contains 0.3 mg of ranibizumab in 
a vial. The unit cost was found through the NMA price database and divided by 3, 
under the assumptions that patients can be accumulated so that “left-over” from one 
injection can be transferred to the next treatment. The unit cost of 0.1 mg of 
ranibizumab was NOK 3,063. The frequency of treatment with ranibizumab was on 
average 11 per year, derived from the ANCHOR study (24). The upper and lower 
bound of the frequency was set to be 14 and 6. 
6.4.2 Other Treatment Costs        
Estimating other treatment costs related to tests, investigations, use of medical 
equipments, nurses, overhead costs etc. were attached with great uncertainties as 
there were no available data on the exact costs of these components. Hence, these 
costs were estimated on the basis of an expert opinion provided by the 
pharmaceutical company Novartis, which is selling both drugs in Europe. As the tests 
and investigations are somewhat identical in the two treatments, the main difference 
in costs was related to the laser treatment given in PDT treatment. The unit costs of 
one treatment of the different strategies were assumed to be NOK 4,500 for PDT 
treatment, and NOK 3,500 for treatment with ranibizumab.  
                                              
27 http://www.legemiddelverket.no/custom/templates/gzInterIFrame____1547.aspx 
28 In Norwegian: Apotekenes utsalgspris (AUP) 
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6.4.3 Costs of Physician Visits 
Under the assumption that both treatment with ranibizumab and PDT lasts for 
approximately one hour, the unit cost was set to be one hour of consultation at a 
specialist in ophthalmology. Fee schedules from the Norwegian Medical 
Association29 were used to estimate this unit cost to be NOK 491 (excl. the patient’s 
charge of NOK 265).  
6.4.4 Costs of Vision Aids 
Because the need of vision aid is closely related to visual acuity, the costs of vision 
aids differ between the health states in my model. Each state was assigned costs that 
were estimated based on an expert opinion by John Engebretsen at MultiOptikk AS, 
Oslo. The estimated costs were calculated based of the average need of relevant 
vision aids within the different health states. The costs were added up based on 
approximate market prices of the different vision aids. Costs related to vision aids 
that were assumed to be relevant for all health states were excluded. Hence, the costs 
related to health state 1 (VA≥20/40) was set to 0. All vision aids that is supposed to 
be returned after the use of a patient were assigned annual costs, estimated by 
equation 3, where E=equivalent annual cost, n=the useful life of the equipment, 
r=discount rate, K=purchase price, with the assumption of no resale value. 
Equation 3: 
r
rEK
n−+−= )1(1  
The lifetime of the products was set to be 5 years, and a discount rate of 4%, in line 
with guidelines from the Ministry of Finance30.  was used in the estimations In cases 
                                              
29 http://www.legeforeningen.no/assets/Normaltariffen_2006.pdf 
30 http://www.regjeringen.no/upload/FIN/Vedlegg/okstyring/Veileder_i_samfunnsokonomiske_analyser.pdf 
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where not all vision aids were returned because of special customisation for the 
patients, the return rate was assumed to be 50%.  
6.4.5 Costs of Home Care 
This cost component consists of the costs related to need of homecare of the patients. 
I assumed that these costs were only relevant for patients in the health state with VA 
< 20160. However, there are great differences in the need for care within this group, 
resulting in large variations of what services they consume, and therefore also 
considerable uncertainties in the actual costs between the patients. Unfortunately, I 
was not able to find available data on what proportion of resource use AMD patients 
consumed of such services. I assumed that they consumed 5 hours of homecare per 
week in general, divided on three visits per week. The unit cost was set as 1 hour of 
“effective care”, and was estimated from the wage rate of home nurses in the public 
sector. I used a price-model from the sector for care and social welfare in the 
municipality of Oslo31 to estimate the mean cost of one 1 hour of care (NOK 314) 
when day-shifts and evening-shifts were considered, under the assumption that 65 % 
of the time spent by home nurses was related to actual treatment of patients. This 
estimate was supplied with unit costs per visit (NOK 54) and administrative costs per 
month (NOK 215) derived from the same price-model. These unit costs together 
resulted in total costs of one year of home care per patient to be NOK 92,617. 
Because I assumed that patients were in perfect health apart from the AMD diagnosis, 
I concluded that it was sufficient with home care. Hence, costs related to being 
institutionalized at nursing homes were excluded. 
                                              
31 http://cpub.www.helse-og-velferdsetaten.oslo.kommune.no/getfile.php/helse-
%20og%20velferdsetaten%20%28HEV%29/Internett%20%28HEV%29/Dokumenter/dokument/omsorg/bakgrunn_for_pris
_brukervalg.pdf 
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6.4.6 Costs of Rehabilitation 
These costs are made up by courses arranged by the Norwegian Association of the 
Blind and Partially Sighted (NABP) for people with severe vision impairment, and 
will only affect the patients in the health state defined as VA < 20/160. An expert 
opinion from the NABP estimated these cost to be NOK 91,700 per person, which 
covers participation and transport. The courses offered by the NABP are provided 
once per person. 
 
Table 2: Cost components used in the model 
Name of model 
parameter Description 
Base case 
value 
Lower 
bound 
Upper 
bound Sources 
cRan05 
Drugcost 0.5mg 
Lucentis 15 315 12 252* 18378* NMA 
cRan03 
Drugcost 0.3mg 
Lucentis 9 189 7 351* 11027* NMA 
cPDT 
Drugcost 
Visudyne 9 790 7 832* 11748* NMA 
cOTCRan 
Other treatment 
costs Lucentis 3 500 2 800 4 200 Expert opinion 
cOTCpdt 
Other treatment 
costs visudyne 4 500 3 600 5 400 Expert opinion 
cPhysVis 
Cost of 
physician visit 491 393 589
Fee schedules from the 
Norwegian Medical 
Association 
cVAids2080 
Cost of vision 
aids in state 2 3 144 2 515 3 773
Expert opinion, student 
opinion 
cVAids20160 
Cost of vision 
aids in state 3 7 186 5 749 8 623
Expert opinion, student 
opinion 
cVAids20160wors
e 
Cost of vision 
aids state 4 16 620 13 296 19 944
Expert opinion, student 
opinion 
cRehab 
Cost of 
rehabilitation, 
state 4 91 700 73 360
110 
040 NABP 
cHome 
Cost of home 
care, state 4 92 617 74 094
111 
140
The sector for care and 
social welfare, 
municipality of Oslo 
*For illustrative purposes 
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6.5 Quality of Life 
The benefits of the two treatments compared are measured in QALYs. Data on 
HRQoL weights are based on the results from an article published by Brown et 
al.(12). The article has used a TTO-model to associate utility values with visual 
acuity levels of the better seeing-eye32. However, the visual acuity levels presented 
did not match exactly to the states in my model, so it was necessary to make some 
adjustments to make the data fit my model. The quality of life weights used in my 
model are therefore based on mean values taken from the article. I also assumed that 
the worst visual acuity level was limited to 20/800 which equals the term “counting 
fingers” in the article. The upper bound of utility value is set to be 0.97, and not 1.0 
because it is assumed that a positive AMD diagnosis will represent some fear of 
future vision loss (12). As the base case values were estimated by the mean of the 
utility values in the VA range, the upper and lower bounds were defined by the 
highest and lowest utility value in the same range. The quality of life weights are 
listed in Table 3. 
 
Table 3: HRQoL weights 
Name of the 
model 
parameter Description  
Base 
case 
value  
Lower 
bound  
Upper 
bound Source  
q2040  VA ≥ 20/40  0.85  0.80  0.97  
Brown et al.(10), student 
assumptions 
q2080  20/40 > VA ≥ 20/80 0.76  0.72  0.80  
Brown et al.(10), student 
assumptions  
q20160  20/80 > VA ≥ 20/160  0.69  0.66  0.72  
Brown et al.(10), student 
assumptions  
q20160worse  VA < 160  0.59  0.52  0.66  
Brown et al.(10), student 
assumptions  
 
 
                                              
32 See appendix 5. 
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6.6 Cost-effectiveness Threshold 
Cost-effectiveness thresholds represent the maximum amount society is willing to 
pay for a unit of health benefit (23). This study used QALYs to express health 
benefits. An article by Kristiansen and Gyrd-Hansen (29), has discussed the need for 
setting a tentative threshold for the soctiety’s willingness to pay for health benefits, 
which can be used by decision-makers in the health care sector when prioritizing 
health care programmes. The Norwegian Department of Finance has suggested this 
threshold to be NOK 425, 000 per QALY (30). Hence, I have used this threshold in 
the analysis of the results. 
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7. RESULTS 
7.1 Costs and Health Consequences 
The expected total costs over 2 years of treatment with PDT per patient were NOK 
198,500 with a total expected health gain of 1.34 QALYs. The incremental costs of 
treatment with 0.3 mg ranibizumab were NOK 116,000 with an incremental health 
gain in QALYs of 0.16, resulting in an ICER of NOK 739,500. This means that 
treating about 6.25 patients with 0.3 mg ranibizumab for 2 years instead of PDT, will 
have the health gain of 1 QALY, which represents a health gain equal to bringing 1 
person from death to perfect health. The ICER of treatment with 0.5 mg ranibizumab 
gave an ICER of NOK 7,976,500. The main findings, when two years of costs and 
two years of QALYs were considered for the three treatment options, are presented in 
Table 4. The results are calculated by TreeAge, which operates with more decimals in 
the calculations than what is presented in the table. All costs are rounded off to the 
nearest amount in NOK 500.  
 
Table 4: Main Results. All costs in Norwegian Kroner (NOK) with a 
discount rate of 4 %. 
Strategy 
Two year 
costs 
Incremental 
costs 
Two year 
QALYs 
Incremental 
QALYs ICER 
PDT 198 500 0 1.34 0 0 
0.3mg Lucentis 314 500 116 000 1.50 0.16 739 500 
0.5mg Lucentis 437 000 122 500 1.51 0.015 7 976 500 
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These results are visualized in Fig. 9, which shows the cost-effectiveness plane for 
the treatment options, with the slope of the lines indicating the ICER. 
 
Figure 9: Cost effectiveness plane of the treatment options 
 
Assuming an incidence of 2440 new cases of neovascular AMD per year, with 40% 
of these receptive to PDT-treatment (6) the annual costs on the health care sector will 
be NOK 98,776,000. Under the same assumption the economical burden on the 
health care sector will be NOK 156,426,000 per year for treatment with 0.3 mg 
ranibizumab and NOK 217,468,000 for treatment with 0.5 mg ranibizumab. 
7.2 Costs of Severe Vison Loss 
If a VA < 20/160 is used as a definition of severe vision loss/blindness, costs related 
to this condition were calculated by the parameter values regarding costs of vision 
aids related to a VA < 20/160, costs of home care and costs of rehabilitation. Because 
the costs of rehabilitation are a one time expense when reaching this condition, the 
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results were presented in mean annual costs33 and total costs34 with a time horizon of 
1, 2 and 5 years with a discount rate of 4%. 
 
Table 5: Annual costs related to severe vision loss/blindness 
Time period Annual costs Total costs 
1 year 200 937 200 937 
2 years 162 096 305 730 
5 years 134 839 600 278 
 
7.3 Sensitivity Analysis 
A one-way sensitivity analysis was performed on all parameters in the model35, 
showing that the drug costs of ranibizumab and the frequency of treatments with 
ranibizumab are the variables having the greatest impact of the results. The lower 
bound, indicating a 20% reduction of the drug price of ranibizumab, makes treatment 
with 0.3 mg ranibizumab borderline cost-effective compared to PDT, with an ICER 
of NOK 486,091. If the frequency of treatments with 0.3 mg ranibizumab is reduced 
to 6 treatments per year (lower bound) with the same effectiveness as those described 
in ANCHOR, this treatment will dominate PDT treatment, meaning that it is less 
costly and more effective. At a price of about NOK 6,900 per dose of Lucentis® 
(excl. VAT), the ICER of treatment with 0.3 mg of ranibizumab would be within the 
threshold of NOK 425,000 implicating that replacing PDT treatment by ranibizumab 
injection would be a cost-effective strategy. This is illustrated in Fig. 10, where the 
horizontally dotted line is representing the ICER threshold and the vertically dotted 
                                              
33 Annual costs in the 5-year time horizon were calculated from equation 3. 
34 In net present value (NPV) 
35 See appendix 6 
 45
line is representing the current drug cost of 0.3 mg ranibizumab. At the point where 
the blue line, representing treatment with 0.3 mg ranibizumab, crosses the 
horizontally dotted line, the treatment is considered cost-effective compared to the 
threshold. With a drug price of Lucentis® of about NOK 3,600 per dose, PDT 
treatment will be dominated. This is indicated by the point in which the blue line 
crosses the red line, which represents PDT treatment, lying on the x-axis. 
 
Figure 10: Incremental cost-effectiveness versus drug cost of ranibizumab 
 
The one-way sensitivity analysis of the frequency of ranibizumab treatment was 
performed and illustrated in the same way in Fig. 11, with ICER threshold as the 
horizontally dotted line, and the average number of treatment with ranibizumab, from 
the ANCHOR study, as the vertically dotted line.  
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Figure 11: Incremental cost-effectiveness versus frequency of treatment 
with ranibizumab 
 
Assuming no change in efficacy from reduced frequency of treatment with 
ranibizumab, the average number of treatments with 0.3 mg ranibizumab must be 
reduced from 11 (base case) to about 9 per year for the treatment to be considered 
cost-effective compared to the ICER threshold. If the treatment frequency is reduced 
to about 6 per year, PDT treatment will be dominated. Treatment with 0.5 mg 
ranibizumab is not depicted in any of the graphs because the ICER is far above NOK 
1,000,000, which is the highest value on the y-axis.  
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8. DISCUSSION 
The ICERs calculated in the model showed results concluding that replacement of 
PDT with ranibizumab is not considered cost-effective in a health care perspective, 
under the base case assumptions. With base case assumptions, the incremental cost 
per QALY with ranibizumab 0.3 mg instead of PDT was about NOK 740,000 while it 
was about NOK 8 millions by increasing the ranibizumab dose to 0.5mg. This implies 
that the use of ranibizumab may not be considered cost-effective in a Norwegian 
context. However, this conclusion must be seen against the limitations of the study 
and the interpretation of the results before it can be applied in a decision-making 
context. The conclusion is also dependent on the perspective of the study. Because of 
the exclusion of indirect costs, this study was performed in a health care perspective, 
regarding costs and consequences related to the health care sector. If the CUA was 
applied in a broader societal perspective the results may be different. It is fair to 
assume that patients suffering from the lowest levels of visual acuity will put demand 
of considerable resources on family members or other volunteers related to time 
costs. Because the effectiveness of treatment with ranibizumab is significantly better 
than PDT treatment (24), this will result in higher costs of PDT treatment because of 
a higher frequency distribution of patients ending up in the most resource consuming 
states, that is those with lowest visual acuity.  According to the aspect of productivity 
losses, people that not yet are retired could also get neovascular AMD. This will also 
increase the costs on those with the most severe vision loss, due to e.g. early 
retirement or special arrangements at the work place. Hence, the results in a societal 
perspective might make treatment with ranibizumab more cost-effective compared to 
treatment with PDT than the results achieved in a health care perspective 
8.1 Methodological Limitations 
Using anti-VEGF treatment with ranibizumab on AMD patients is a relatively new 
kind of treatment. Because of this, the long-term effects are uncertain, as the 
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published results are restricted to the efficacy results of one year of treatment. Based 
on an expert opinion I assumed the two-year results to be quite constant as the one-
year result. How the efficacy of treatment with ranibizumab will be beyond two years 
of treatment are attached with uncertainties and might have considerably effects 
related to the cost-effectiveness of the treatment options. The TAP report No. 8, 
presented the long-term effects (5-year results) of PDT treatment, concluding that the 
visual acuity outcomes were stable from 2 to 5 years. If the long-term effects of 
ranibizumab treatment provide benefits beyond 2 years compared to PDT, this means 
that the effectiveness of ranibizumab compared to PDT are underestimated in terms 
of QALYs gained. This scenario will make treatment with ranibizumab more cost-
effective over a prolonged time perspective. If the long-term effects of ranibizumab 
indicate that the efficacy results decline over the time horizon towards the long-term 
effects of PDT, this will have an opposite effect on the ICERs of ranibizumab.  
 
The costs and consequences of adverse events, both ocular and non-ocular, were 
excluded in the study. The ANCHOR study and the FOCUS36 study have reported an 
increased risk of serious adverse ocular37 and non-ocular38 events with higher dosage 
of ranibizumab treatment. The differences were, however, not statistically significant. 
The more common ocular adverse events that were more frequently in the 
ranibizumab-treated groups compared with PDT included mild to moderate 
inflammation, conjunctival hemorrhage, increased intraocular pressure, eye pain and 
vitrous floaters. Treatment of the adverse effects will imply increased costs of 
treatment with ranibizumab. In addition, the QALYs gained from ranibizumab 
injection could be overestimated as the adverse events would have negative impact 
                                              
36 A phase I-II, randomized, single masked study evaluating the safety, tolerability and efficacy of ranibizumab in 
combination with PDT compared to PDT alone (7). 
37 Uveitis and endolphthalmitis (7). 
38 Cerebral vascular events and myocardinal infarctions (7). 
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on HRQoL. Hence, the exclusion of costs and consequences related to adverse effects 
will overestimate the cost-effectiveness of treatment with ranibizumab. It is also 
worth mentioning that in the same way as long-term efficacy of treatment with 
ranibizumab is uncertain, so are the long-term effects related to the adverse events. 
Costs related to injuries caused by vision loss were also excluded in the model. 
Including these costs will disfavour treatment with PDT because of the higher 
proportion of patients ending up in the health state with lowest VA. All these costs 
were excluded because of the limitation of available data. In the costs related to 
physician visits, the patient’s charge of NOK 265 was excluded. However, the 
sensitivity analysis showed that the parameter describing the costs of physician visits 
had minor impacts on the results of the study. 
 
Another methodological limitation is regarding uncertainties in the parameter values. 
The results of the study are based on a decision analytic model were all the inputs are 
assigned parameter values. Hence, variations and uncertainties in these parameter 
values will affect the main results. Input data, especially regarding the costs, are 
attached with great uncertainties and variations. This was a result of lack of available 
data, which made these inputs to a large extent to be based on assumptions and 
estimated guesses. However, the sensitivity analysis implicated that the variables with 
greatest impact of the results were the drug price of ranibizumab and the frequency of 
treatments with ranibizumab. These two variables are among those that are attached 
with least uncertainties, as the drug price is given by NMA, and the average number 
of treatments with ranibizumab is based on randomized controlled trials (RCT).  
 
There is also reason to comment on the different health states used in the model. 
These states were used in an attempt to assign costs related to different degrees of 
vision loss. The health states are divided according to levels of visual acuity. 
However, the variations of visual acuity within each health state can be substantial, 
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leading to great differences in the need for care, vision aids etc. This will again have 
consequences on the cost side, resulting that costs of being in each of the health states 
must be regarded as values with possible large uncertainties.  
 
The health benefits of this study were based on efficacy results of RCTs, from the 
ANCHOR-study and the TAP-studies. Even though RCTs provide the best type of 
information on which to base an analysis (31), there are some limitation in my study 
regarding the probabilities used in the model. This is related to the fact that I had to 
adapt the efficacy results to fit into my model. Both studies reported the primary 
outcomes in proportion of patients losing fewer than 15 letters/3 lines of visual 
acuity. Supplied with subgroup analysis these proportions were used to find the 
probability of ending up in the 4 different health states when an initial VA of 20/80 
was assumed. However, the distribution of patients with different VA within each 
state is uncertain. This might have considerable consequences because resources 
consumed by the patients are closely related to the level of visual acuity, so also with 
the health benefits in terms of QALYs. Hence, the actual costs and health benefits 
related to each health state would differ depending on the distribution within the 
different health states. If the distribution within a certain health state is skewed 
towards a health state with higher visual acuity, the actual costs will be lower, while 
the health gain in QALYs will be higher than what the model predicts. The opposite, 
with increased costs and decreased health gains, will be the case if the distribution is 
skewed towards a health state with a lower VA. Another limitation regarding the 
probabilities was that the two-year results of the ANCHOR study are not published, 
leading to the probabilities of year two in the model to be estimated based on an 
expert opinion.    
 
Because the patient group that entered into my model was set to be people with 
neovascular AMD between 70-80 years old, with a mean age of 75, the assumption of 
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the initial health state of patients being in perfect health apart from the AMD 
diagnosis is unlikely to hold. This assumption was chosen in an attempt to measure 
and value quality of life aspects strictly related to visual acuity. However, it is fair to 
assume that people in this age group also would suffer from other disorders or 
disabilities. As a result of this, the incremental costs related to nursing care might be 
overestimated in the analysis because some proportion in this age group already will 
receive nursing care based on other medical conditions. This will be in disfavour of 
PDT treatments that have most patients in the health state that receives nursing care. 
However, the costs of being institutionalized at nursing homes are excluded. This 
might be a considerable cost item that would have the opposite effect, in being 
favourable for the cost-effectiveness outcome of PDT treatment. The age of the 
patient group would also expect that costs and consequences of mortality are likely to 
be of relevance. These aspects were excluded in the model because there were no 
empirical data to document a significant difference in mortality between the treatment 
options considered.  
 
The limitations regarding uncertainties in the long-term effectiveness of ranibizumab, 
and also the coherence between treatment frequency and efficacy, are probably 
among the most import aspects when considering ranibizumab injection to be a cost-
effective treatment option compared to PDT. Hence, there is a need for more certain 
data on these aspects to achieve more certain results that be used in a decision making 
context to draw conclusions regarding the cost effectiveness of ranibizumab 
compared to PDT.  
8.2 Findings of Other Cost-Effectiveness Studies 
It was not found any other studies comparing the incremental costs and incremental 
health benefits of PDT replacement by treatment with ranibizumab on AMD patients. 
This is probably because of ranibizumab’s first approval for use was such short time 
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ago, and that the published efficacy results of ranibizumab treatment are restricted to 
the one-year results. 
 
Prior cost-effectiveness studies on PDT primarily use placebo as a comparator (e.g. 
TAP-studies). As economic evaluations involve comparative analysis of alternative 
courses of action(22), my study can not be used to decide whether PDT treatment is 
cost-effective by itself. Hence, comparisons with such studies are not appropriate. 
However, since PDT treatment is the conventional treatment of neovascular AMD, it 
must be assumed that it is considered cost-effective in the sense that the treatment is 
widely adopted. 
 
Published cost-effectiveness studies on ranibizumab are very limited. The few articles 
related to cost-effectiveness and ranibizumab/Lucentis®, are using bevacizumab/ 
Avastin® 39 as comparator. This comparison is currently a hot prospect in the 
treatment of neovascular AMD. Ranibizumab is the antibody fragment derived from 
the complete humanized antibody, called bevacizumab (20). As a result of this, 
bevacizumab have similar medical effects as ranibizumab in the interaction with 
VEGF. However, bevacizumab is not designed for intravitreal use, but for 
intravenous treatment of colorectal cancer, and for this reason the drug price of 
bevacizumab is much lower than ranibizumab per mg. The reason for the low drug 
price of bevacizumab compared to ranibizumab is due to each single dose is 
purchased in a larger volume. A single dose of Avastin® contains 100mg of 
bevacizumab in a 4 ml vial, while Lucentis® is sold in doses of 0.3 ml containing 0.3 
mg of ranibizumab. From the price database of NMA, the price of Avastin is NOK 
2,851 per dose while the price of Lucentis is NOK 9,189, excl.VAT. Because of the 
large volume of Avastin, one single dose can be used to treat more patients because 
                                              
39 The commercial name for bevacizumab is Avastin®. 
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of the small volume needed in intravitreal injections. As a result of this the drug price 
of bevacizumab is 40-50 times lower than the drug price of ranibizumab (32). This 
major difference in drug prices have resulted in bevacizumab being used off-licence 
in AMD-treatment. There are, however, moral and ethical dilemmas with such off-
licence use, because bevacizumab is not approved for intravitreal injections. In 
addition the efficacy and safety results for intravitreal use have not been targeted by 
randomized controlled trials. Published articles comparing bevacizumab to 
ranibizumab suggests that it is unlikely that ranibizumab will be cost-effective 
treatment option with the current drug prices (20;32;33) . The Norwegian Knowledge 
Centre for the Health Services is currently doing a study comparing ranibizumab and 
bevacizumab. 
8.3 Discussion of Results 
The efficacy results of treatment with ranibizumab are based on monthly intravitreal 
injections. However, in practice the average treatment frequency is reduced. The 
ongoing PIER and PRONTO studies are investigating the results of less frequent 
treatments with ranibizumab (7). It is suggested that fewer treatments might obtain 
similar efficacy results as those described in the ANCHOR and MARINA studies. 
There are, however, not been published any results regarding the impact on efficacy 
from frequency reduction. Because the total treatment costs, both related to drug costs 
and other treatment costs, represent a major variable in estimating the cost 
effectiveness of ranibizumab, the results from PIER and PRONTO might have 
considerable effects when determining if ranibizumab is a cost effective treatment 
option. The lack of data from PIER and PRONTO made me use the study treatment 
described from ANCHOR when documenting the effectiveness of ranibizumab. The 
efficacy results in ANCHOR were based on an average of 11.1 treatments with 
ranibizumab given to each patient per year. When it is argued that the number of 
treatments with ranibizumab in clinical practice can be reduced, it is also important to 
notice that the impact of this reduction on the effectiveness of the treatment is 
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uncertain. The results of the sensitivity analysis indicated that a frequency reduction 
in the average number of treatments with ranibizumab from 11 to 9 per year, would 
make treatment with 0.3 mg ranibizumab cost-effective compared to PDT treatment 
when no reduction in efficacy is assumed. The cost-effectiveness of ranibizumab 
must also be seen, as mentioned earlier in the discussion, in relation to how the long-
term effects of treatment will be.  
 
From the sensitivity analysis the drug cost, and the number of treatments with 
ranibizumab were the variables with the greatest impact of the ICER. However, there 
was also an indication that the effectiveness of PDT in the first year could be of 
importance. If the effectiveness of PDT is reduced, in this case meaning that the all 
the base case probabilities attached to PDT treatment is replaced by the lower bounds, 
the results gave an ICER of replacement with 0.3 mg ranibizumab to be NOK 
308,896, which must be considered cost-effective. This result, however, must be 
considered as a worst case scenario of PDT treatment, because the accumulated 
reduction in all these probabilities40 will be transferred to the probability of ending up 
in the worst health state, with VA < 20/160. This is because the probability attached 
to the worst health state is denoted, #, in the TreeAge model, which means that this 
probability is calculated by subtracting the other probabilities from 141. This situation 
being the case must be considered unlikely, when compared to the RCTs, because it 
indicates a proportion of patients losing fewer than 3-lines/15 letters to be 43.5%. The 
proportion of patients losing fewer than 3-lines/15 letters of VA are the primary 
outcomes of both the ANCHOR- and TAP studies. The ANCHOR study has reported 
this proportion to be 64.3% while TAP Report No.8 has reported this proportion to be 
67%42. The one-way sensitivity analysis gave an ICER for 0.3 mg ranibizumab 
                                              
40 Name of parameters in the model: p2040PDT, p2080PDT, p20160PDT. 
41 # = (1-p2040PDT-p2080PDT-p20160PDT) 
42 This proportion is based on results after 2 years. The 1-year results must be assumed to be even higher. 
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treatment to be in the range of NOK 512,000 -533,500 when the base case 
probabilities where changed one at the time in the parameters attached to probabilities 
in PDT treatment. .   
 
The results of this study are based on patients with predominantly classic neovascular 
AMD. This is an aggressive form of the disease, as it is associated with more severe 
and more rapid vision loss compared to the minimally classic and occult forms (24). 
PDT treatment with verteporfin has proved to be effective on predominantly classic 
CNV and occult (with no classic) CNV compared to no treatment (34). The treatment 
with ranibizumab, however, is also providing benefits to patients with the minimally 
classic form of AMD (25), with the result that more patients are receptive to 
treatment with ranibizumab than treatment with verteporfin. 
8.4 Policy Implication and Conclusion 
The conclusion of this study is that, with the current price of Lucentis® and an 
average treatment frequency as described in the ANCHOR-study, replacing PDT 
treatment by ranibizumab on patients with neovascular AMD is not cost effective 
when the threshold is set to NOK 425,000 per QALY gained. There is, however, a 
need of documenting the long-term effects of treatment with ranibizumab, and also 
documenting the relationship between number of treatments given and efficacy, when 
considering the cost effectiveness of ranibizumab. Treatment with 0.3 mg 
ranibizumab appears to be a cost-effective treatment if the price per dose were 
reduced to about NOK 6,900 (excl. VAT). 
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9. APPENDIX 
Appendix 1: Prevalence of AMD in the US  
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Appendix 2: Norwegian population   
The table shows data from Statistics Norway of the Norwegian population above 40 
years old in 2006. 
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Appendix 3: Primary outcomes of ANCHOR and TAP  
The tables show the primary outcomes of ANCHOR and TAP, which represents the 
proportion of patients losing fewer than 3 lines / 15 letters of visual acuity. The table 
from ANCHOR is supplied with subgroup analysis. 
PRIMARY OUTCOMES FROM ANCHOR: 
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ANCHOR SUBGROUP ANALYSIS: 
 
PRIMARY OUTCOMES TAP REPORT NO. 8: 
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Appendix 4: Probabilities used in the Treeage model 
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Appendix 5: Time trade-off utility values associated with 
visual acuity levels. 
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Appendix 6: One-way sensitivity analysis on all model 
parameters 
The sensitivity analysis shows the ICER of treatment with 0.3 mg ranibizumab 
compared to PDT treatment, when the lower and upper bounds on each model 
parameter are considered. The results on the ICER of treatment with 0.5 mg 
ranibizumab were excluded in the table because all these results were far above the 
cost-effectiveness threshold of NOK 425,000. Hence, the model parameters regarding 
only the treatment with 0.5 mg of ranibizumab are also excluded. 
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